Form 4: Madrigal Pharmaceuticals SVP and CFO, Mardi Dier, Reports Stock Sales

Mardi Dier, SVP and CFO of Madrigal Pharmaceuticals, reported the sale of common stock to cover tax obligations and pursuant to a pre-arranged trading plan.

Summary

• Mardi Dier, the SVP and CFO of Madrigal Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 3, 2025, Dier sold 1,187 shares of common stock at $325.89 per share to cover tax withholding obligations related to vesting restricted stock units.
• Additionally, Dier sold 774 shares at a weighted average price of $323.5357 per share, with individual prices ranging from $323.38 to $323.63.
• These sales were executed under a Rule 10b5-1 trading plan adopted on November 13, 2024.
• Following these transactions, Dier beneficially owns 6,914 shares of Madrigal Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market.

Key Dates